ライフサイエンスコーパス: subtherapeutic

1 renchyma by the IV, IT or IVT routes will be subtherapeutic.

2 d the baseline dosage of acyclovir to become subtherapeutic.

3 R348 10 mg/kg was subtherapeutic.

4 when the international normalized ratio was subtherapeutic.

5 ntrations were consistently documented to be subtherapeutic.

6 ) to determine the effect of therapeutic and subtherapeutic (0-1 cm H(2)O) nasal continuous positive

7 ere assigned to either therapeutic (n=59) or subtherapeutic (59) nCPAP (about 1 cm H(2)O pressure) fo

8 eated with 1 month's therapeutic (n = 15) or subtherapeutic adaptive servoventilation.

9 al vertebrate species, we proposed that such subtherapeutic administration alters the population stru

10 Concentrations correlated with subtherapeutic and therapeutic blood levels.

11 Subtherapeutic and therapeutic R507 and R545 doses prolo

12 Administration of subtherapeutic antibiotic therapy increased adiposity in

13 We generated a model of adiposity by giving subtherapeutic antibiotic therapy to young mice and eval

14 To prevent supratherapeutic or subtherapeutic anticoagulation, these patients must be i

15 Status epilepticus etiologies included subtherapeutic antiepileptic drugs (43%), alcohol or oth

16 More patients with therapeutic vs subtherapeutic ART had resistance (n = 73): no major mut

17 Absence of NRTI mutations and subtherapeutic ART preswitch were associated with failur

18 Nonadherence, suggested by subtherapeutic ART with/without major resistance mutatio

19 time more than twice the control time) with subtherapeutic bivalirudin anticoagulation (activated pa

20 djuvant therapy enabled the use of typically subtherapeutic carboplatin doses without decreasing effi

21 comparison to a monkey that received sCR1 + subtherapeutic CCS (rejected at 11 days) and a control t

22 Subtherapeutic CNI concentrations were common in the fir

23 y, and withdrawal of the azole may result in subtherapeutic CNI concentrations.

24 Carboplatin was delivered at the subtherapeutic concentration of 62.5 microg.

25 ut significantly enhanced Treg generation at subtherapeutic concentrations (P<0.01).

26 Lumefantrine concentrations suggested subtherapeutic concentrations in at least 2 cases.

27 Combined RAPA and IVIG at subtherapeutic concentrations inhibits cell proliferatio

28 Agricultural use of antimicrobials in subtherapeutic concentrations is increasing in response

29 treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs.

30 ated gene transfer results in persistent yet subtherapeutic concentrations of factor IX and requires

31 reptogramin, virginiamycin, has been used at subtherapeutic concentrations to promote the growth of f

32 self-reported health status compared with a subtherapeutic control.

33 - allograft recipients treated with a brief, subtherapeutic course of cyclosporin A maintained their

34 Third we assessed whether a subtherapeutic course of cyclosporine would potentiate e

35 d with blocking anti-MCP-1 mAb plus a brief, subtherapeutic course of rapamycin had long-term islet a

36 Compared with results without CPAP, subtherapeutic CPAP did not affect any measured polysomn

37 Subtherapeutic CsA and RS-61443 monotherapy groups devel

38 Addition of FTY720 therapy to a subtherapeutic CsA immunosuppressive regimen delays the

39 cant difference was noted in the presence of subtherapeutic CSA or FK levels (15.4% vs. 13.9%, P=NS).

40 The described dosing schedule resulted in subtherapeutic daclizumab levels in liver transplant rec

41 when donor sMHC were combined with a single subtherapeutic dosage of cyclosporine.

42 to show that piceatannol, when combined with subtherapeutic dosages of CsA, prevents graft rejection,

43 RAPA at a subtherapeutic dose of 0.1 mg/kg worsened glucose metabo

44 Finally, a subtherapeutic dose of anti-CD154 Ab or CTLA4-Ig, which

45 Treatment of animals with BX471 and a subtherapeutic dose of cyclosporin (2.5 mg/kg), which is

46 days after transplantation with or without a subtherapeutic dose of cyclosporine.

47 on immunosuppression, the combination at the subtherapeutic dose of each drug may be synergistically

48 follow-up, small sample size, and a possibly subtherapeutic dose of etanercept.

49 A subtherapeutic dose of local radiotherapy in combination

50 ntravenously administered saline or a single subtherapeutic dose of MP (5 mg/kg) as the parent drug (

51 (allograft) immunosuppression with a single subtherapeutic dose of MP delivered as a liver-targeted

52 In contrast, the subtherapeutic dose of ropinirole generated only modest

53 The subtherapeutic dose of ropinirole improved the use of pr

54 These data support the use of the subtherapeutic dose of ropinirole in a chronic model of

55 MOPC-315 tumor bearers when combined with a subtherapeutic dose of the chemotherapeutic agent melpha

56 oups: saline; carboplatin (31.25 mug/20 muL, subtherapeutic dose); 2-DG (250 mg/kg); 2-DG (500 mg/kg)

57 02), which included four patients treated at subtherapeutic doses and 24 patients treated at 960 mg t

58 on therapy with CsA + RS-61443 at these same subtherapeutic doses developed acute rejection (P < or =

59 bits lymphocyte proliferation, was tested at subtherapeutic doses in combination with cyclosporine (C

60 Treatment with subtherapeutic doses of a MEK-1/2 inhibitor delayed arth

61 The collateral effects of feeding subtherapeutic doses of antibiotics to agricultural anim

62 The combined adoptive transfer of subtherapeutic doses of both TRP1-specific TCR transgeni

63 2) Subtherapeutic doses of CsA do not prolong allograft sur

64 nted to Lewis or control dark agouti rats on subtherapeutic doses of cyclosporin.

65 ll function in vitro and, when combined with subtherapeutic doses of cyclosporine (CsA), prolongs all

66 nt effects of delivered vIL-10 alone or with subtherapeutic doses of cyclosporine A (CsA) on paramete

67 more pronounced effects in combination with subtherapeutic doses of DEX.

68 However, when administered with subtherapeutic doses of opioids or the enkephalinase inh

69 Combination treatment with subtherapeutic doses of Peg IFN-alpha 2a and Nutlin-3 in

70 Therapeutic and subtherapeutic doses of R507 (60 and 15 mg/kg 2 times pe

71 Subtherapeutic doses of rapamycin plus TIM-1-specific an

72 he potent inhibition of CYP3A4 by ritonavir, subtherapeutic doses of ritonavir are used to increase p

73 common tertiary structure and inhibition by subtherapeutic doses of the antibipolar drug lithium.

74 within the first 3 months of treatment or on subtherapeutic doses were excluded.

75 ts receiving antidepressants were prescribed subtherapeutic doses, and two (18%) of the 11 who were p

76 of a triple-drug regimen using each agent at subtherapeutic doses, namely BQR (2.0 mg/kg/q.o.d.), CsA

77 At subtherapeutic doses, neither anti-ST2L mAb nor CpG alon

78 g antimitotic regimens, enabling efficacy of subtherapeutic doses.

79 rations that routinely use antimicrobials in subtherapeutic doses.

80 owever, treatment failure, noncompliance and subtherapeutic dosing were often reported.

81 Fifty-five percent (n = 44/80) had subtherapeutic drug concentrations preswitch.

82 Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/coloniz

83 Subtherapeutic drug levels can be caused by poor adheren

84 reakthrough event are underlying disease and subtherapeutic drug levels.

85 Our results suggest that subtherapeutic expression levels of near full-length, me

86 linical trials have suffered from transient, subtherapeutic expression of human fVIII transgenes.

87 es of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents.

88 1.30-1.97) anticoagulation compared with the subtherapeutic group (12%).

89 There was a trend for the subtherapeutic groups to have higher vascular scores.

90 of MCP-1 binding to CCR2 in conjunction with subtherapeutic immunosuppression can have profound effec

91 uto- or allotransplantation, with or without subtherapeutic immunosuppression to temporarily characte

92 The fluconazole concentration was considered subtherapeutic in 40% of the patients.

93 international normalized ratio (INR) levels: subtherapeutic (INR <2), therapeutic (INR, 2-3), and sup

94 , paroxysmal atrial fibrillation (OR: 5.19), subtherapeutic international normalized ratio (OR: 7.37)

95 ering continuous positive airway pressure to subtherapeutic levels for 3 minutes during non-REM sleep

96 However, in the presence of subtherapeutic levels of CsA, graft survival time was si

97 ith a gamma-globin/MGMT vector initially had subtherapeutic levels of red cells expressing gamma-glob

98 No subtherapeutic levels were observed postpartum.

99 Additional preliminary studies suggest that subtherapeutic levels, including microlevels of lithium,

100 closporine, one of which was excluded due to subtherapeutic levels.

101 eared safe, circulating F.IX levels remained subtherapeutic (< 1%).

102 wed by a subrenal capsular implantation of a subtherapeutic mass of 25 islets from young (3 months) o

103 were randomly assigned therapeutic NCPAP or subtherapeutic NCPAP (about 1 cm H2O) for 1 month.

104 not significantly, from 20.0 to 23.5 min on subtherapeutic NCPAP (between treatments p<0.005).

105 therapeutic NCPAP, and from 15.0 to 13.0 on subtherapeutic NCPAP (between treatments, p<0.0001).

106 107 men entered the study: 53 received subtherapeutic NCPAP and 54 therapeutic NCPAP.

107 Subtherapeutic NCPAP did not alter the overnight number

108 Therapeutic NCPAP was superior to subtherapeutic NCPAP in all primary outcome measures.

109 lood pressure by 2.5 mm Hg (SE 0.8), whereas subtherapeutic nCPAP increased blood pressure by 0.8 mm

110 leep apnoea compared with a control group on subtherapeutic NCPAP.

111 ed with the most robust control intervention subtherapeutic nCPAP.

112 d vitality were 1.68 (therapeutic) and 0.97 (subtherapeutic) NCPAP (between treatments p<0.0001).

113 artificially low or high doses resulting in subtherapeutic or adverse effects.

114 osis is crucial to prevent toxic effects and subtherapeutic or supratherapeutic drug dosing.

115 e day of transplantation in conjunction with subtherapeutic oral cyclosporine (CsA, 10 mg/kg/day, day

116 +10 posttransplantation in conjunction with subtherapeutic oral cyclosporine.

117 tal; two of these cases were associated with subtherapeutic partial thromboplastin time values.

118 was similar: 5.4 h (therapeutic) and 4.6 h (subtherapeutic) per night.

119 r in the 16 partially adherent patients with subtherapeutic plasma levels (N=13, 81%) than in the 46

120 plasma levels than in adherent patients with subtherapeutic plasma levels.

121 In one recipient with subtherapeutic RAD blood levels on day 7 posttransplant,

122 a 2-log decline in plasma MTX levels to the subtherapeutic range within 5 minutes of CPG2 administra

123 When combined with a subtherapeutic regimen of rapamycin, CXCR3-173 mAb induc

124 These results confirm that subtherapeutic RS-61443 + CsA combination therapy is eff

125 mbined treatment with low-dose rapamycin and subtherapeutic T(reg) numbers on the development of tran

126 Transient subtherapeutic tacrolimus concentrations may induce acut

127 indow may result in allograft dysfunction as subtherapeutic tacrolimus levels predispose to episodes

128 ion had a statistically greater incidence of subtherapeutic tacrolimus trough levels on postoperative

129 studies in drug development, individualized subtherapeutic tests of drug metabolism, carbon dating a

130 Among these patients, 46%, 35%, and 19% had subtherapeutic, therapeutic, and supratherapeutic admiss

131 Serial passage in subtherapeutic transferrin concentrations resulted in no

132 The placebo group had subtherapeutic ultrasound to the knee at an intensity of

133 erapy only (24.8% [95% CI, 24.3%-25.3%]), or subtherapeutic warfarin (25.8% [95% CI, 25.0%-26.6%]); u

134 therapy only (8.1% [95% CI, 7.8%-8.3%]), or subtherapeutic warfarin (8.8% [95% CI, 8.3%-9.3%]).

135 erapeutic anticoagulation; 12751 (13.5%) had subtherapeutic warfarin anticoagulation (INR <2) at the